8th Dec 2015 07:34
LONDON (Alliance News) - Hutchison China MediTech Ltd on Tuesday said its Hutchison MediPharma Ltd research and development subsidiary has initiated the phase 3 registration study for its fruquintinib drug for lung cancer patients in China.
Preparations for site selection for the trial started in August this year, and the first patient was dosed on Tuesday, the company said.
Hutchison said the primary endpoint for the trials is overall survival for the patients, with secondary endpoints including progression-free survival, an objective response rate, and disease control rate.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed